益丰药房(603939) - 2024 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2024 reached ¥5,970,923,210.35, representing a year-on-year increase of 13.39%[5] - The net profit attributable to shareholders was ¥406,753,106.09, reflecting a growth of 20.89% compared to the same period last year[5] - Basic earnings per share (EPS) stood at ¥0.40, an increase of 19.15% year-on-year[5] - Total operating revenue for Q1 2024 reached ¥5,970,923,210.35, an increase of 13.4% compared to ¥5,266,053,201.98 in Q1 2023[29] - Net profit for Q1 2024 was ¥445,951,883.35, representing a 17.4% increase from ¥379,869,656.04 in Q1 2023[31] - Earnings per share for Q1 2024 were ¥0.40, compared to ¥0.34 in Q1 2023, reflecting a 17.6% increase[31] - Total equity attributable to shareholders reached ¥10,393,858,921.24 in Q1 2024, up from ¥9,804,432,476.56 in Q1 2023, indicating a growth of 6.0%[25] Cash Flow and Liquidity - The net cash flow from operating activities decreased by 49.56%, primarily due to the normalization of medical insurance reimbursements following a public health event[9] - The net cash flow from operating activities decreased to CNY 650,107,205.26 in Q1 2024, compared to CNY 1,288,846,164.43 in Q1 2023, reflecting a decline of approximately 49.5%[34] - Cash inflow from financing activities totaled CNY 1,785,372,000.00 in Q1 2024, with a net cash flow of CNY 1,356,321,367.58, compared to a net outflow of CNY -341,525,797.58 in Q1 2023[36] - The ending cash and cash equivalents balance increased to CNY 4,313,037,671.22 in Q1 2024, up from CNY 2,551,940,192.22 in Q1 2023[36] - The cash flow from operating activities showed a decrease in net cash flow, indicating potential challenges in maintaining operational efficiency compared to the previous year[34] Assets and Liabilities - Total assets at the end of the reporting period amounted to ¥26,161,823,616.23, up 8.39% from the end of the previous year[7] - The company's total liabilities amounted to 11,088,641,783.26 RMB, compared to 11,269,471,260.25 RMB at the end of 2023, showing a decrease of about 1.6%[24] - The company's total liabilities as of Q1 2024 amounted to ¥15,093,808,483.45, an increase from ¥13,689,451,532.80 in the previous year[25] - Cash and cash equivalents increased to 5,370,180,357.94 RMB from 3,565,905,738.81 RMB, reflecting a growth of approximately 50.5%[23] - Accounts receivable rose to 2,356,242,795.04 RMB, up from 2,138,274,319.88 RMB, indicating an increase of about 10.2%[23] - Inventory decreased slightly to 3,738,258,397.54 RMB from 3,807,963,660.86 RMB, a decline of approximately 1.8%[23] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 15,096[10] - The top ten shareholders held a combined 81.54% of the company's shares, with the largest shareholder owning 21.65%[11] Strategic Initiatives - The company plans to continue its market expansion and acquisition strategy to enhance its competitive position in the industry[18] - In Q1 2024, the company added 701 new stores, including 364 self-built stores, 166 acquired stores, and 171 franchise stores, resulting in a total of 13,920 stores by the end of the reporting period, a net increase of 670 stores[16] - The company completed five acquisition projects during the reporting period, with total acquisition prices amounting to 7,025 million RMB, involving 55 to 67 stores per project[18][19] Research and Development - Research and development expenses for Q1 2024 were ¥9,772,260.99, significantly higher than ¥4,637,452.27 in Q1 2023, marking a 110.0% increase[29] Other Financial Metrics - The company reported non-recurring gains of ¥7,311,972.36 for the period[9] - The return on equity (ROE) was 4.06%, showing a slight increase of 0.21% compared to the previous year[7] - The company reported investment income of ¥14,930,288.87 in Q1 2024, compared to ¥4,603,497.68 in Q1 2023, showing a substantial increase of 224.0%[29] - Other comprehensive income after tax for Q1 2024 was -¥44,204,850.00, a decrease from ¥90,606,909.49 in Q1 2023[31]